Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics.

Bulitta JB, Jiao Y, Landersdorfer CB, Sutaria DS, Tao X, Shin E, Höhl R, Holzgrabe U, Stephan U, Sörgel F.

Pharmaceutics. 2019 Jul 10;11(7). pii: E323. doi: 10.3390/pharmaceutics11070323.

2.

Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding.

Shah NR, Bulitta JB, Kinzig M, Landersdorfer CB, Jiao Y, Sutaria DS, Tao X, Höhl R, Holzgrabe U, Kees F, Stephan U, Sörgel F.

Pharmaceutics. 2019 Jun 18;11(6). pii: E286. doi: 10.3390/pharmaceutics11060286.

3.

Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.

Jiao Y, Moya B, Chen MJ, Zavascki AP, Tsai H, Tao X, Sutaria DS, Louie A, Boyce JD, Deveson Lucas D, Kim TH, Tsuji BT, Bonomo RA, Drusano GL, Bulitta JB.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00425-19. doi: 10.1128/AAC.00425-19. Print 2019 Jul.

PMID:
30988147
4.

Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Bulitta JB, Hope WW, Eakin AE, Guina T, Tam VH, Louie A, Drusano GL, Hoover JL.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02307-18. doi: 10.1128/AAC.02307-18. Print 2019 May. Review.

5.

Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.

Rees VE, Deveson Lucas DS, López-Causapé C, Huang Y, Kotsimbos T, Bulitta JB, Rees MC, Barugahare A, Peleg AY, Nation RL, Oliver A, Boyce JD, Landersdorfer CB.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02538-18. doi: 10.1128/AAC.02538-18. Print 2019 Apr.

PMID:
30745381
6.

Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics.

Kim TH, Bulitta JB, Kim DH, Shin S, Shin BS.

Int J Pharm. 2019 Feb 10;556:276-286. doi: 10.1016/j.ijpharm.2018.12.007. Epub 2018 Dec 11.

PMID:
30543888
7.

Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved in situ Absorption Method in Rats.

Kim TH, Paik SH, Chi YH, Bulitta JB, Lee DY, Lim JY, Chung SE, Song CH, Jeong HM, Shin S, Shin BS.

Pharmaceutics. 2018 Oct 3;10(4). pii: E174. doi: 10.3390/pharmaceutics10040174.

8.

Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.

Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01150-18. doi: 10.1128/AAC.01150-18. Print 2018 Nov.

9.

First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.

Jiao Y, Kim TH, Tao X, Kinzig M, Landersdorfer CB, Drescher SK, Sutaria DS, Moya B, Holzgrabe U, Sörgel F, Bulitta JB.

Eur J Pharm Sci. 2018 Oct 15;123:416-428. doi: 10.1016/j.ejps.2018.07.054. Epub 2018 Aug 1.

PMID:
30076955
10.

Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model.

Pires de Mello CP, Tao X, Kim TH, Vicchiarelli M, Bulitta JB, Kaushik A, Brown AN.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00967-18. doi: 10.1128/AAC.00967-18. Print 2018 Sep.

11.

Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, Tao X, Wittau M, Tsuji BT, Zavascki AP, Shin BS, Drusano GL, Sörgel F, Landersdorfer CB.

Clin Pharmacokinet. 2019 Feb;58(2):143-156. doi: 10.1007/s40262-018-0678-x. Review.

PMID:
29936678
12.

First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae.

Sutaria DS, Moya B, Green KB, Kim TH, Tao X, Jiao Y, Louie A, Drusano GL, Bulitta JB.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00282-18. doi: 10.1128/AAC.00282-18. Print 2018 Jun.

13.

Correction to: Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD).

Montagnat OD, Webster GR, Bulitta JB, Landersdorfer C, Wyber R, Sheel M, Carapetis JR, Boyd BJ.

Drug Deliv Transl Res. 2018 Jun;8(3):863. doi: 10.1007/s13346-018-0511-y.

PMID:
29546503
14.

Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Yadav R, Rogers KE, Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00078-18. doi: 10.1128/AAC.00078-18. Print 2018 May.

15.

Determination of the small RNA GcvB regulon in the Gram-negative bacterial pathogen Pasteurella multocida and identification of the GcvB seed binding region.

Gulliver EL, Wright A, Lucas DD, Mégroz M, Kleifeld O, Schittenhelm RB, Powell DR, Seemann T, Bulitta JB, Harper M, Boyce JD.

RNA. 2018 May;24(5):704-720. doi: 10.1261/rna.063248.117. Epub 2018 Feb 12.

16.

Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.

Landersdorfer CB, Rees VE, Yadav R, Rogers KE, Kim TH, Bergen PJ, Cheah SE, Boyce JD, Peleg AY, Oliver A, Shin BS, Nation RL, Bulitta JB.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02055-17. doi: 10.1128/AAC.02055-17. Print 2018 Apr.

17.

Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD).

Montagnat OD, Webster GR, Bulitta JB, Landersdorfer C, Wyber R, Sheel M, Carapetis JR, Boyd BJ.

Drug Deliv Transl Res. 2018 Jun;8(3):729-739. doi: 10.1007/s13346-018-0482-z. Erratum in: Drug Deliv Transl Res. 2018 Mar 15;:.

PMID:
29404981
18.

Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.

Bergen PJ, Bulitta JB, Sime FB, Lipman J, McGregor MJ, Millen N, Paterson DL, Kirkpatrick CMJ, Roberts JA, Landersdorfer CB.

Diagn Microbiol Infect Dis. 2018 May;91(1):69-76. doi: 10.1016/j.diagmicrobio.2017.12.019. Epub 2018 Jan 3.

PMID:
29395712
19.

Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.

Landersdorfer CB, Yadav R, Rogers KE, Kim TH, Shin BS, Boyce JD, Nation RL, Bulitta JB.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02053-17. doi: 10.1128/AAC.02053-17. Print 2018 Apr.

20.

Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens.

Pires de Mello CP, Tao X, Kim TH, Bulitta JB, Rodriquez JL, Pomeroy JJ, Brown AN.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01983-17. doi: 10.1128/AAC.01983-17. Print 2018 Jan.

21.

Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.

Yadav R, Bulitta JB, Wang J, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01268-17. doi: 10.1128/AAC.01268-17. Print 2017 Dec.

22.

Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.

Yadav R, Bulitta JB, Schneider EK, Shin BS, Velkov T, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00722-17. doi: 10.1128/AAC.00722-17. Print 2017 Dec.

23.

Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.

Kim TH, Shin S, Kim S, Bulitta JB, Weon KY, Joo SH, Ma E, Yoo SD, Park GY, Kwon DR, Jeong SW, Lee DY, Shin BS.

Molecules. 2017 Sep 10;22(9). pii: E1515. doi: 10.3390/molecules22091515.

24.

Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.

Kim TH, Shin S, Shin JC, Bulitta JB, Weon KY, Yoo SD, Park GY, Jeong SW, Kwon DR, Min BS, Woo MH, Shin BS.

Molecules. 2017 Sep 7;22(9). pii: E1488. doi: 10.3390/molecules22091488.

25.

Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac.

de Miranda Silva C, Rocha A, Tozatto E, da Silva LM, Donadi EA, Dalla Costa T, Lanchote VL, Schmidt S, Bulitta JB.

AAPS J. 2017 Nov;19(6):1814-1825. doi: 10.1208/s12248-017-0138-9. Epub 2017 Sep 5.

PMID:
28875479
26.

Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era.

Bulman ZP, Chen L, Walsh TJ, Satlin MJ, Qian Y, Bulitta JB, Peloquin CA, Holden PN, Nation RL, Li J, Kreiswirth BN, Tsuji BT.

MBio. 2017 Jul 25;8(4). pii: e00540-17. doi: 10.1128/mBio.00540-17.

27.

Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.

Bulitta JB, Paik SH, Chi YH, Kim TH, Shin S, Landersdorfer CB, Jiao Y, Yadav R, Shin BS.

Eur J Pharm Sci. 2017 Sep 30;107:32-44. doi: 10.1016/j.ejps.2017.06.008. Epub 2017 Jun 7.

PMID:
28599987
28.

Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli.

Smith NM, Bulman ZP, Sieron AO, Bulitta JB, Holden PN, Nation RL, Li J, Wright GD, Tsuji BT.

J Antimicrob Chemother. 2017 Aug 1;72(8):2297-2303. doi: 10.1093/jac/dkx121.

29.

The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases.

Intensive Care Med. 2017 Jul;43(7):1021-1032. doi: 10.1007/s00134-017-4780-6. Epub 2017 Apr 13. Review.

PMID:
28409203
30.

Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.

Zavascki AP, Klee BO, Bulitta JB.

Expert Rev Anti Infect Ther. 2017 Jun;15(6):519-526. doi: 10.1080/14787210.2017.1316193. Epub 2017 Apr 17. Review.

PMID:
28375030
31.

Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.

Lenhard JR, Thamlikitkul V, Silveira FP, Garonzik SM, Tao X, Forrest A, Soo Shin B, Kaye KS, Bulitta JB, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2017 May 1;72(5):1415-1420. doi: 10.1093/jac/dkx002.

32.

Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02642-16. doi: 10.1128/AAC.02642-16. Print 2017 May.

33.

Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.

Bulman ZP, Ly NS, Lenhard JR, Holden PN, Bulitta JB, Tsuji BT.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e00096-16. doi: 10.1128/AAC.00096-16. Print 2017 Apr.

34.

High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.

Lenhard JR, Smith NM, Bulman ZP, Tao X, Thamlikitkul V, Shin BS, Nation RL, Li J, Bulitta JB, Tsuji BT.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01268-16. doi: 10.1128/AAC.01268-16. Print 2017 Mar.

35.

Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.

Yadav R, Bulitta JB, Nation RL, Landersdorfer CB.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01011-16. doi: 10.1128/AAC.01011-16. Print 2017 Jan.

36.

Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.

Kim TH, Shin S, Bulitta JB, Youn YS, Yoo SD, Shin BS.

Mol Pharm. 2017 Jan 3;14(1):53-65. doi: 10.1021/acs.molpharmaceut.6b00677. Epub 2016 Dec 12.

PMID:
27809538
37.

Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.

Wittau M, Paschke S, Kurlbaum M, Scheele J, Ly NS, Hemper E, Kornmann M, Henne-Bruns D, Bulitta JB.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e00952-16. doi: 10.1128/AAC.00952-16. Print 2017 Jan.

38.

Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Lenhard JR, Gall JS, Bulitta JB, Thamlikitkul V, Landersdorfer CB, Forrest A, Nation RL, Li J, Tsuji BT.

Int J Antimicrob Agents. 2016 Dec;48(6):719-724. doi: 10.1016/j.ijantimicag.2016.07.024. Epub 2016 Sep 20.

39.

High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Lenhard JR, Bulitta JB, Connell TD, King-Lyons N, Landersdorfer CB, Cheah SE, Thamlikitkul V, Shin BS, Rao G, Holden PN, Walsh TJ, Forrest A, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2017 Jan;72(1):153-165. Epub 2016 Sep 15.

40.

Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

Rees VE, Bulitta JB, Oliver A, Tsuji BT, Rayner CR, Nation RL, Landersdorfer CB.

J Antimicrob Chemother. 2016 Nov;71(11):3157-3167. Epub 2016 Aug 11.

41.

Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.

Rao GG, Ly NS, Bulitta JB, Soon RL, San Roman MD, Holden PN, Landersdorfer CB, Nation RL, Li J, Forrest A, Tsuji BT.

J Antimicrob Chemother. 2016 Nov;71(11):3148-3156. Epub 2016 Aug 3.

42.

Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats.

Kim TH, Kim MG, Shin S, Chi YH, Paik SH, Lee JH, Yoo SD, Youn YS, Bulitta JB, Joo SH, Jeong SW, Weon KY, Shin BS.

BMC Pharmacol Toxicol. 2016 Jul 26;17(1):35. doi: 10.1186/s40360-016-0080-y.

43.

Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii.

Rao GG, Ly NS, Diep J, Forrest A, Bulitta JB, Holden PN, Nation RL, Li J, Tsuji BT.

Int J Antimicrob Agents. 2016 Sep;48(3):331-6. doi: 10.1016/j.ijantimicag.2016.06.006. Epub 2016 Jul 12.

44.

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach.

Garonzik SM, Lenhard JR, Forrest A, Holden PN, Bulitta JB, Tsuji BT.

PLoS One. 2016 Jun 10;11(6):e0156131. doi: 10.1371/journal.pone.0156131. eCollection 2016.

45.

Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.

Bergen PJ, Bulitta JB, Kirkpatrick CM, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Lipman J, Roberts JA, Landersdorfer CB.

J Antimicrob Chemother. 2016 Sep;71(9):2509-20. doi: 10.1093/jac/dkw153. Epub 2016 May 26.

PMID:
27231278
46.

Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens.

Cheah SE, Johnson MD, Zhu Y, Tsuji BT, Forrest A, Bulitta JB, Boyce JD, Nation RL, Li J.

Sci Rep. 2016 May 19;6:26233. doi: 10.1038/srep26233.

47.

Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.

Tsuji BT, Landersdorfer CB, Lenhard JR, Cheah SE, Thamlikitkul V, Rao GG, Holden PN, Forrest A, Bulitta JB, Nation RL, Li J.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3913-20. doi: 10.1128/AAC.02831-15. Print 2016 Jul.

48.

Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.

Cheah SE, Li J, Tsuji BT, Forrest A, Bulitta JB, Nation RL.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3921-33. doi: 10.1128/AAC.02927-15. Print 2016 Jul.

49.

Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling.

Jacobs M, Grégoire N, Couet W, Bulitta JB.

PLoS Comput Biol. 2016 Mar 11;12(3):e1004782. doi: 10.1371/journal.pcbi.1004782. eCollection 2016 Mar.

50.

Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa.

Ly NS, Bulman ZP, Bulitta JB, Baron C, Rao GG, Holden PN, Li J, Sutton MD, Tsuji BT.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2870-80. doi: 10.1128/AAC.02377-15. Print 2016 May.

Supplemental Content

Loading ...
Support Center